A692

New Jersey A692 limits upfront costs for oral anticancer medications for persons covered under certain health benefits plans.

New Jersey A692 aims to limit upfront costs for oral anticancer medications for individuals covered under specific health benefits plans. The bill amends existing laws to ensure that health insurers, the State Health Benefits Program, and the School Employees’ Health Benefits Program cover oral anticancer medications on a basis no less favorable than intravenous anticancer medications. It prohibits health benefits plans from requiring patients to pay additional upfront costs or out-of-pocket expenses for oral anticancer medications, except for copayments, deductibles, or coinsurance.